Navigation Links
First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
Date:10/23/2007

SAN FRANCISCO, Oct. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) announced preclinical data presented at the 19th annual AACR-NCI-EORTC Symposium show its bis-platinate drug candidates, CT-47613 and CT-47609, kill tumors refractory to currently marketed platinum agents carboplatin, cisplatin and oxaliplatin. These compounds could enter human clinical trials in late 2008.

"Bis-platinates represent a promising new class of platinum-based chemotherapy drugs with a potential broad spectrum of anti-tumor activity. Anti-cancer drugs containing platinum are a cornerstone therapy for a wide range of tumor types including ovarian, testicular, colorectal, head and neck, and lung cancer," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These bis-platinates, unlike the currently approved platinum compounds, contain two platinum atoms and work by binding to and damaging both strands of DNA making it much more difficult for cancer cells to repair the damage. The preclinical studies presented at this meeting suggest these compounds are substantially more active than the existing monoplatinates -- especially against platinum-resistant tumors. These agents could represent a significant advance in the treatment of a wide variety of cancers."

Novel bisplatinum complexes characterized by an improved in vitro plasma protein binding and in vivo efficacy on xenograft models (Abstract A267)

Scientists from CTI-Europe presented data on two novel bis-platinum complexes, CT-47613 and CT-47609. When tested in animal models of ovarian cancer and colon cancer, the bis-platinates were significantly more potent than the two most commonly used platinum based chemotherapy drugs, carboplatin and cisplatin and oxaliplatin. Importantly these agents demonstrated potent anti-tumor activity in tumors with either acquired or intrinsic resistance to cisplatin or carboplatin, representing the first such class of binuclear platinum based
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. Midwest life science stocks sizzle in a tepid first quarter
3. Morgridge Institute for Research seeks first CEO
4. Sonic Foundry reports first cash-positive quarter
5. Angel investors commit $12.7B in first half of `06
6. Aurora team implants Wisconsins first total artificial heart
7. First half of 2006 roundup: Big Pharma trumps biotech
8. GE announces first installation of Discovery VCT
9. GE Healthcare enjoys robust growth in first quarter
10. Madison asks for wireless bids; airport, downtown would be first
11. Tech Digest: Inacom, PKWare at Infosecurity, Firstlogic, Teklynx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... a chain of carbon atoms can turn it from ... University scientists. , Stretching the material known as carbyne ... by just 3 percent can begin to change its ... mechanically activated nanoscale electronics and optics. , The finding ... appears in the American Chemical Society journal Nano ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, ... with depression. According to a study published by ... quarters of depressed patients have insomnia symptoms, and ... depressed adults and 10% of older patients, with ... distress, have a major impact on quality of ...
(Date:7/18/2014)... , July 18, 2014  Neogen Corporation (Nasdaq: ... Snyder , Neogen,s chief operating officer and president, has ... will work as a consultant going forward on special ... Snyder has been in this position since September 2013. ... by James Herbert , who has been Neogen,s ...
(Date:7/18/2014)... Hungary & Cambridge, MA (PRWEB) July 18, 2014 ... , headquartered in Budapest with US offices in ... HLA™ - a combination Assay and Software product ... (NGS), for use on the Illumina® MiSeq sequencing ... through collaboration with The Children’s Hospital of Philadelphia ...
Breaking Biology Technology:Carbyne morphs when stretched 2Carbyne morphs when stretched 3Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3Omixon Launches Holotype HLA for NGS-based HLA Genotyping 2Omixon Launches Holotype HLA for NGS-based HLA Genotyping 3
... large measure the ability to tune out negativity, author ... of southeastern Wisconsin technology professionals. , ,Kawasaki, managing partner ... "Art of the Start" and several other business books, ... of eInnovate. He poked some good-natured fun at politicians, ...
... may have an expo floor to rival any industry trade show, but ... a sale. , , The BIO Chicago show floor, the size ... globe. "I don't expect any of our end-user customers in the ... of Milwaukee-based Neurognostics said. "This is a probably a better ...
... A stem cell scientist from Harvard University dropped by Wisconsin's ... a hint of admiration, that it was abuzz with activity. ... Wisconsin exhibit than anywhere else I've been on the (exhibit) ... foot traffic at a trade show even one of ...
Cached Biology Technology:Beating back the bozos is an innovation must, says Kawasaki 2As BIO shows mass of competition, hunt for partners is on 2As BIO shows mass of competition, hunt for partners is on 3In competitive biotech world, Wisconsin can't afford to fall behind 2In competitive biotech world, Wisconsin can't afford to fall behind 3
(Date:7/21/2014)... and Dr. Mary Lou Applewhite Distinguished Professor in Department ... to an article in the scientific journal Nature ... into Primate Biology and Evolution," published on July 20. ... mobile elements that move by a sort of "copy ... important because it is the first "New World" monkey ...
(Date:7/21/2014)... La. Dr. Mark DeCoster, the James E. ... Louisiana Tech University, will present as an invited ... at the Biopolis Research and Development Center in ... faculty member in Louisiana Tech,s Institute for Micromanufacturing, ... 2D and 3D cell and tissue models." ...
(Date:7/21/2014)... see an innovation and think, "Of course! Why didn,t ... thoughts of our own invention, sparking ideas and building ... the International Space Station Program Science Office,s new 15-book ... have going on in orbit, their mental wheels may ... encourage investigators to propose new research and potentially make ...
Breaking Biology News(10 mins):LSU's Mark Batzer contributes to Nature Genetics article on marmoset genome 2Louisiana Tech University professor presents at International Bioprinting Congress 2International Space Station researcher guides aim to maximize science 2International Space Station researcher guides aim to maximize science 3International Space Station researcher guides aim to maximize science 4
... at the Southwest Foundation for Biomedical Research (SFBR) in ... levels of bad cholesterol to accumulate in the blood ... studied a strain of laboratory opossums developed at SFBR ... (LDL) cholesterol when fed a standard low-cholesterol diet, but ...
... 14, 2010: 5:00 p.m. U.S. Eastern Time) A new ... groups reveals an ominous finding: most of the world,s ... tradeare now clustered in just six percent of their ... scattered across Asia that are now the last hope ...
... published in the Sept. 15 edition of the Journal ... Edward H. Shortliffe, MD, PhD, points out that although ... role that information management and access play in healthcare ... informatics competency being developed in America,s future corps of ...
Cached Biology News:Scientists find gene for high cholesterol in blood 2Last strongholds for tigers identified in new study 2Last strongholds for tigers identified in new study 3Informatics = essential MD competency 2
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
Biology Products: